Novo Nordisk’s Revenue Growth Surges 22.3% Amid GLP-1 Drug Success
Key Takeaways Novo Nordisk’s financial growth has accelerated sharply since 2020, propelled by its GLP-1 receptor agonist drugs, Ozempic and Wegovy. The company’s revenue compound annual growth rate (CAGR) jumped...